Surrogate Endpoints, Accelerated Approval, and Confirmatory Trials

Introduction

Most drugs are approved based on proof of clinical benefit: overall survival, symptom improvement, or disease-free survival measured in large Phase III trials. But the FDA's Accelerated Approval pathway allows approval based on surrogate endpoints (biomarkers or lab measurements that are "reasonably likely to predict clinical benefit") before full clinical benefit is proven.

This pathway gets drugs to patients faster, but it creates a unique valuation challenge: the drug is on the market generating revenue, but there is residual regulatory risk that the approval could be withdrawn if confirmatory trials fail or are not completed.

Surrogate Endpoint

A biomarker or laboratory measurement used as a substitute for a direct measure of clinical benefit. Common examples include: overall response rate (ORR) as a surrogate for survival in oncology, viral load suppression as a surrogate for AIDS progression, and HbA1c reduction as a surrogate for diabetes complications. Surrogate endpoints are accepted for Accelerated Approval when they are "reasonably likely to predict clinical benefit," a lower evidentiary bar than "proven to predict clinical benefit."

Under Accelerated Approval, the drug receives full marketing authorization and can be sold commercially. In exchange, the sponsor must complete post-marketing confirmatory trials that demonstrate actual clinical benefit (typically overall survival or another definitive clinical outcome). If the confirmatory trial confirms benefit, the approval converts to standard approval. If the confirmatory trial fails or the sponsor does not complete it, the FDA can initiate proceedings to withdraw the approval.

Healthcare bankers model accelerated-approved products with a probability-weighted revenue discount reflecting the risk of confirmatory trial failure and potential withdrawal:

The FDA Omnibus Reform Act (FDORA, enacted in 2022) strengthened FDA's authority to enforce confirmatory trial requirements and expedite withdrawal proceedings. Under FDORA, FDA can require confirmatory trials to be underway at the time of accelerated approval, set specific completion timelines, and use an expedited process to withdraw approvals when trials are not completed or fail.

Since FDORA's enactment, the FDA has withdrawn several accelerated approvals where sponsors failed to verify clinical benefit, signaling a shift toward more rigorous enforcement.

Surrogate endpoints and accelerated approval are one type of binary event in the broader landscape of catalyst-driven biotech valuation.